Nature 513, 436–439 (2014); doi:10.1038/nature13540
This Letter should have declared the following competing financial interests: “The fibroblast growth factor (FGF) molecules and related methods of use reported in this study are covered in the following published patent applications and counterparts that derive priority: (1) PCT/US2011/032848, held by R.M.E., M.D., J.W.J., and J.M.S. (handled by Salk OTD); (2) PCT/US2013/044589, held by M.M., R.G., R.M.E., M.D. and J.M.S. (handled by NYU Office of Industrial Liaison/Technology Transfer); (3) PCT/US2013/044594, held by M.M., R.G., R.M.E., M.D. and J.M.S. (handled by NYU Office of Industrial Liaison/Technology Transfer); and (4) PCT/US2013/044592, held by M.M. and R.G. (handled by NYU Office of Industrial Liaison/Technology Transfer).”.
Additional information
The online version of the original article can be found at 10.1038/nature13540
Rights and permissions
About this article
Cite this article
Suh, J., Jonker, J., Ahmadian, M. et al. Correction: Corrigendum: Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature 520, 388 (2015). https://doi.org/10.1038/nature14304
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature14304
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
